IRIS
BOCCHIA, MONICA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 24.479
EU - Europa 20.184
AS - Asia 12.190
SA - Sud America 2.400
AF - Africa 589
OC - Oceania 39
Continente sconosciuto - Info sul continente non disponibili 17
Totale 59.898
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 24.123
GB - Regno Unito 4.343
RU - Federazione Russa 4.217
CN - Cina 4.059
SG - Singapore 3.825
IT - Italia 2.863
IE - Irlanda 2.621
BR - Brasile 1.983
UA - Ucraina 1.386
VN - Vietnam 1.256
SE - Svezia 1.199
FR - Francia 1.186
DE - Germania 988
HK - Hong Kong 969
FI - Finlandia 651
KR - Corea 629
IN - India 354
ZA - Sudafrica 251
CA - Canada 168
BD - Bangladesh 166
NL - Olanda 165
AR - Argentina 153
IQ - Iraq 131
TR - Turchia 120
JP - Giappone 115
MX - Messico 115
NG - Nigeria 98
PL - Polonia 97
PK - Pakistan 80
ES - Italia 70
BE - Belgio 68
EC - Ecuador 60
ID - Indonesia 54
AT - Austria 53
CZ - Repubblica Ceca 52
MA - Marocco 51
SA - Arabia Saudita 49
UZ - Uzbekistan 49
KE - Kenya 48
VE - Venezuela 48
CO - Colombia 41
IR - Iran 41
EG - Egitto 36
CL - Cile 32
PY - Paraguay 32
AU - Australia 31
CI - Costa d'Avorio 30
PH - Filippine 29
LT - Lituania 28
AE - Emirati Arabi Uniti 26
MY - Malesia 24
PE - Perù 24
TN - Tunisia 23
AZ - Azerbaigian 21
DO - Repubblica Dominicana 21
DZ - Algeria 21
EE - Estonia 21
NP - Nepal 21
CH - Svizzera 19
JO - Giordania 19
GR - Grecia 18
IL - Israele 18
KZ - Kazakistan 18
LB - Libano 14
OM - Oman 14
BO - Bolivia 13
PT - Portogallo 13
BG - Bulgaria 12
JM - Giamaica 12
SK - Slovacchia (Repubblica Slovacca) 12
UY - Uruguay 12
ET - Etiopia 11
PS - Palestinian Territory 11
RO - Romania 11
HN - Honduras 10
LV - Lettonia 10
RS - Serbia 10
TH - Thailandia 10
AL - Albania 9
DK - Danimarca 9
EU - Europa 8
HR - Croazia 8
KG - Kirghizistan 8
KH - Cambogia 8
PA - Panama 8
TT - Trinidad e Tobago 8
HU - Ungheria 7
LK - Sri Lanka 7
BH - Bahrain 6
BY - Bielorussia 6
NZ - Nuova Zelanda 6
QA - Qatar 6
XK - ???statistics.table.value.countryCode.XK??? 6
GE - Georgia 5
LA - Repubblica Popolare Democratica del Laos 5
LU - Lussemburgo 5
MD - Moldavia 5
MN - Mongolia 5
NO - Norvegia 5
AM - Armenia 4
Totale 59.826
Salva come PNG Salva come JPEG
Città #
Southend 3.769
Dallas 3.067
Dublin 2.604
Fairfield 2.449
Singapore 2.264
Ashburn 1.924
Chandler 1.322
Houston 1.255
Woodbridge 1.232
Moscow 1.139
Santa Clara 1.116
Jacksonville 1.091
Wilmington 991
Seattle 961
Hong Kong 923
Hefei 883
Beijing 877
Cambridge 777
Ann Arbor 647
Seoul 625
San Jose 582
Siena 538
Princeton 514
The Dalles 442
Nanjing 392
Ho Chi Minh City 371
Los Angeles 365
Lauterbourg 348
Helsinki 311
Milan 307
Council Bluffs 284
Hanoi 284
Munich 265
Boardman 251
New York 243
Johannesburg 217
Florence 215
São Paulo 190
San Mateo 175
Buffalo 166
Rome 139
San Diego 137
Dearborn 126
Dong Ket 122
Nanchang 112
Bengaluru 108
Shanghai 106
London 103
Abuja 90
Orem 90
Redondo Beach 87
Tokyo 81
Hebei 79
Shenyang 79
Tianjin 78
Columbus 75
Nuremberg 74
Frankfurt am Main 71
Lappeenranta 68
Turku 67
Chicago 65
Warsaw 65
Rio de Janeiro 63
Kunming 58
Baghdad 57
Brussels 57
Da Nang 57
Denver 55
Chennai 54
Stockholm 54
Düsseldorf 52
Haiphong 52
Izmir 52
Menlo Park 52
Montreal 51
Toronto 51
Jiaxing 50
Jinan 50
Atlanta 48
Changsha 48
Guangzhou 48
San Francisco 47
Tashkent 44
Turin 42
Dhaka 40
Norwalk 40
Phoenix 40
Amsterdam 39
Belo Horizonte 39
Brooklyn 39
Poplar 37
Portsmouth 37
Falls Church 34
Hangzhou 34
Washington 34
Zhengzhou 34
Curitiba 33
Brno 32
Porto Alegre 32
Abidjan 30
Totale 40.114
Salva come PNG Salva come JPEG
Nome #
VEXAS syndrome: a new paradigm for adult-onset monogenic autoinflammatory diseases 862
null 398
Mycosis Fungoides: a therapeutical review 375
MACOP-B versus F-MACHOP regimen in the treatment of high grade Non-Hodgkin’s Lymphomas 350
A novel potent class I HDAC inhibitor reverses the STAT4/p66Shc apoptotic defect in B cells from chronic lymphocytic leukemia patients 330
Decreased plasma endogenous soluble RAGE, and enhanced adipokine secretion, oxidative stress and platelet/coagulative activation identify non-alcoholic fatty liver disease among patients with familial combined hyperlipidemia and/or metabolic syndrome 317
A novel class of oxazepine-based anti-cancer agents induces cell death in primary human CLL cells and efficiently reduces tumor growth in Eμ-TCL1 mice through the JNK/STAT4/p66Shc axis 316
Flow Cytometry Assessment of CD26+ Leukemic Stem Cells in Peripheral Blood: A Simple and Rapid New Diagnostic Tool for Chronic Myeloid Leukemia 305
Efficacy and safety of the neonatal Fc receptor inhibitor efgartigimod in adults with primary immune thrombocytopenia (ADVANCE IV): a multicentre, randomised, placebo-controlled, phase 3 trial 303
Cardiovascular toxicity in patients with chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors in the real-life practice: Identification of risk factors and the role of prophylaxis 302
Circulating CD34+/CD38-/CD26+ Leukemia Stem Cells along Chronic Myeloid Leukemia progression: differences between Chronic, Accelerated and Blast Phase 291
Antibody and B-cell responses in myelofibrosis patients after the third doses of mRNA SARS-CoV-2 vaccines 288
Additional chromosomal abnormalities in Philadelphia-positive clone: Adverse prognostic influence on frontline imatinib therapy: A GIMEMA Working Party on CML analysis 288
Residual peripheral blood CD26+leukemic stem cells in chronic myeloid leukemia patients during TKI therapy and during treatment-free remission 287
A P210-derived multipeptide vaccine (CMLVAX100) induces reduction of “stable” minimal residual disease in chronic myeloid leukemia (CML) patients during treatment with Imatinib or alpha-Interferon 286
Atherothrombotic Risk and TKIs Treatment In Chronic Myeloid Leukemia Patients: A Role For Genetic Predisposition and Pro-Inflammatory/Pro-Oxidative Status? 285
Low-level TP53 mutational load antecedes clonal expansion in chronic lymphocytic leukaemia 281
Genetic predisposition and induced pro-inflammatory/pro-oxidative status may play a role in increased atherothrombotic events in nilotinib treated chronic myeloid leukemia patients 276
Leukemic cell-secreted interleukin-9 suppresses cytotoxic T cell-mediated killing in chronic lymphocytic leukemia 275
A central nervous system CD56 positive multiple myeloma patient with a t(11;14) (q11;q32): A case report 274
Ectopic ILT3 controls BCR-dependent activation of Akt in B-cell chronic lymphocytic leukemia 273
ABL mutations in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic resistance to imatinib are associated with a greater likelihood of progression to blast crisis and shorter survival: A study by the GIMEMA working party on chronic myeloid leukemia 273
Carriers of ADAMTS13 Rare Variants Are at High Risk of Life-Threatening COVID-19 272
Multicentre phase III trial on fludarabine, cytarabine (Ara-C), and idarubicin versus idarubicin, Ara-C and etoposide for induction treatment of younger, newly diagnosed acute myeloid leukaemia patients. 269
Intravenous (IV) bortezomib infusion after non-response to subcutaneous bortezomib administration can induce transitory responses in multiple myeloma patients: Are some patients more sensitive to IV bortezomib? 268
Atherothrombotic risk assessment during tyrosine kinase inhibitors treatment in chronic myeloid leukemia patients: new insight? 267
The BCR-ABL1 transcript type influences response and outcome in Philadelphia chromosome-positive chronic myeloid leukemia patients treated frontline with imatinib 267
Lower dose rituximab is active in adults patients with idiopathic thrombocytopenic purpura 267
Unravelling the response of chronic lymphocytic leukemia to a novel class of anticancer agents, the pyrrolonaphthoxazepines (PNOXs) 258
Human cytotoxic T lymphocytes form dysfunctional immune synapses with B cells characterized by non-polarized lytic granule release 257
Second generation proteasome inhibitors in multiple myeloma 255
Adherence and future discontinuation of tyrosine kinase inhibitors in chronic phase chronic myeloid leukemia. A patient-based survey on 1133 patients 255
The hOCT1 and ABCB1 polymorphisms do not influence the pharmacodynamics of nilotinib in chronic myeloid leukemia 250
A case of i(11)(q10) as sole cytogenetic abnormality in a patient with acute lymphoblastic leukemia 248
Long-Term Safety of Rapid Daratumumab Infusions in Multiple Myeloma Patients 248
A der(1)t(1;21)(p36.3;q22) in a patient with acute myelogenous leukemia M2 245
Achieving a major molecular response at the time of a complete cytogenetic response (CCgR) predicts a better duration of CCgR in imatinib-treated chronic myeloid leukemia patients 245
Genetic predisposition and induced pro-inflammatory/pro-oxidative status may explain increased atherothrombotic risk during TKI treatment in chronic myeloid leukemia patients 243
Central nervous system multiple myeloma 242
Real-world experience with decitabine as a first-line treatment in 306 elderly acute myeloid leukaemia patients unfit for intensive chemotherapy 240
BCR-ABL Derived Peptide Vaccine in Chronic Myeloid Leukemia Patients with Molecular Minimal Residual Disease During Imatinib: Interim Analysis of a Phase 2 Multicenter GIMEMA CML Working Party Trial 238
Clinical impact of CD200 expression in patients with acute myeloid leukemia and correlation with other molecular prognostic factors 236
Durable response after VNCOP-B and rituximab in an elderly patient with high-grade B-cell lymphoma 235
A simple prognostic scoring system for newly diagnosed cytogenetically normal acute myeloid leukemia: Retrospective analysis of 530 patients 235
High CD200 expression is associated with poor prognosis in cytogenetically normal acute myeloid leukemia, even in FlT3-ITD-/NPM1+ patients 233
Study of gene polymorphisms as predictors of treatment efficacy and toxicity in patients with indolent non-hodgkin lymphomas and mantle cell lymphoma receiving bendamustine and rituximab 232
Complete molecular response in CML after p210 BCR-ABL1-derived peptide vaccination 230
Identification of a Novel P190-Derived Breakpoint Peptide Suitable for Peptide Vaccine Therapeutic Approach in Ph+ Acute Lymphoblastic Leukemia Patients. 229
The Polycomb BMI1 Protein Is Co-expressed With CD26+ in Leukemic Stem Cells of Chronic Myeloid Leukemia 229
Lenalidomide and temozolomide combination in a very elderly patient with CNS relapse of diffuse large B-cell lymphoma 228
Peptide vaccines for hematological malignancies: a missed promise? 227
A BRAF Negative Classic Hairy Cell Leukemia Patient in Long Lasting Complete Remission after Rituximab and Pentostatin 226
Incidence of bacterial and fungal infections in newly diagnosed acute myeloid leukaemia patients younger than 65 yr treated with induction regimens including fludarabine: retrospective analysis of 224 cases 225
A case of acquired factor XIII deficiency secondary to plasmablastic lymphoma 225
Vaccination of patients with chronic myelogenous leukemia with bcr-abl oncogene breakpoint fusion peptides generates specific immune responses 224
Overview of Anti-SARS-CoV-2 Immune Response Six Months after BNT162b2 mRNA Vaccine 222
Dexamethasone plus rituximab yields higher sustained response rates than dexamethasone monotherapy in adults with primary immune thrombocytopenia 221
Orbital/ocular inflammatory involvement in VEXAS syndrome: Data from the international AIDA network VEXAS registry 220
Radiotherapy plus rituximab as first-line regimen for localized follicular lymphoma 218
A solitary uterine relapse in T-cell Acute Lymphoblastic Leukaemia: CT features and pathologic correlation 217
A fatal unsuspected case of acquired A hemophilia. Misleading role of therapy with acetylsalicylic acid? 217
Transmembrane Transporters hOCT1 and SLCO1B3 Polymorphisms Could Have a Role in Patients Affected By Chronic Myeloid Leukemia Treated with Nilotinib 215
New perspectives for patients with primary CNS lymphoma 214
Evaluation of residual CD34(+) Ph(+) progenitor cells in chronic myeloid leukemia patients who have complete cytogenetic response during first-line nilotinib therapy. 213
Evaluation of the prognostic role of tumour-associated macrophages in newly diagnosed classical Hodgkin lymphoma and correlation with early FDG-PET assessment 213
Efficacy and safety of eltrombopag during conception and first trimester of pregnancy in a case of refractory severe immune thrombocytopenia 213
Emerging drugs in chronic myelogenous leukaemia 212
Real word evidence on rituximab utilization: Combining administrative and hospital-pharmacy data 211
Efficacy and safety of rituximab plus bendamustine for gastric marginal zone lymphoma 211
Carfilzomib, lenalidomide, and dexamethasone in relapsed refractory multiple myeloma: a prospective real-life experience of the Regional Tuscan Myeloma Network 208
Frontline imatinib treatment of chronic myeloid leukemia: no impact of age on outcome, a survey by the GIMEMA CML Working Party 208
Variant Philadelphia translocations: Molecular-cytogenetic characterization and prognostic influence on frontline imatinib therapy, a GIMEMA working party on CML analysis 208
FLT3 inhibitors in the management of acute myeloid leukemia 207
A novel t(6;7)(p24;q21) in a chronic myelocytic leuckemia in complete cytogenetic remission after therapy with imatinib mesylate 206
Treatment of smoldering multiple myeloma 206
Single agent lenalidomide activity in multiple myeloma relapse evidenced uniquely by CT/PET 206
Daratumumab efficacy in extramedullary orbital myeloma 206
A case of bone lesion in a patient with relapsed chronic lymphocytic leukemia and review of the literature 205
Antibody response in myelofibrosis patients after three doses of mRNA SARS-CoV-2 vaccine 204
Anaplastic large cell lymphoma (CD30+/Ki-1+): results of a prospective clinico-pathological study of 69 cases 203
Chronic myeloid leukaemia with extreme thrombocytosis at presentation: Incidence, clinical findings and outcome 203
Primary Nasopharyngeal Hodgkin Lymphoma 202
Imatinib does not impair specific antitumor T-cell immunity in patients with chronic myeloid leukemia 201
CD30 positive (non-anaplastic) peripheral T-cell lymphoma of the thyroid gland 200
Long-term outcome of chronic myeloid leukemia patients treated frontline with imatinib 200
First reported case of secondary mixed phenotype acute leukemia after multiple myeloma 200
Pilot study of gemtuzumab ozogamicin (GO), fludarabine, cytarabine and idarubicin combined regimen (GO-FLAI) as first-line induction therapy plus GO alone as consolidation therapy for elderly acute myeloid leukemia patients. 199
Effect of a p210 multipeptide vaccine associated with imatinib or interferon in patients with chronic myeloid leukaemia and persistent residual disease: a multicentre observational trial. 199
Moxetumomab pasudotox in relapsed/refractory hairy cell leukemia 199
Development and implementation of the AIDA international registry for patients with Schnitzler's syndrome 198
Thrombotic thrombocytopenic purpura secondary to an occult adenocarcinoma 198
Ruxolitinib Rapidly Reduces Acute Respiratory Distress Syndrome in COVID-19 Disease. Analysis of Data Collection From RESPIRE Protocol 198
Azacitidine Low-Dose Schedule In Low-Risk Myelodysplastic Syndromes. Preliminary Results of a Multicenter Phase II Study 197
Efficacy and safety of rituximab plus low-dose oral fludarabine and cyclophosphamide as first-line treatment of elderly patients with indolent non-Hodgkin lymphomas 195
Pleural effusion and molecular response in dasatinib-treated chronic myeloid leukemia patients in a real-life Italian multicenter series 193
Evolving treatments in multiple myeloma patients with renal failure 192
Frontline Dasatinib Treatment in a “Real-Life” Cohort of Patients Older than 65 Years with Chronic Myeloid Leukemia 192
Managing chronic myeloid leukemia for treatment-free remission: A proposal from the GIMEMA CML WP 192
Hodgkin lymphoma in the elderly: new perspectives and a 10-year monocenter real-life experience 192
Hyperlipidemia in a myeloma patient after bortezomib treatment 191
Totale 24.508
Salva come PNG Salva come JPEG
Categoria #
all - tutte 185.690
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 185.690
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20211.238 0 0 0 0 0 0 0 0 0 408 390 440
2021/20223.602 262 436 248 322 150 148 136 139 198 395 413 755
2022/20235.140 326 339 617 698 500 1.011 128 468 521 68 338 126
2023/20244.575 178 119 361 331 173 1.015 1.381 397 62 126 87 345
2024/20259.604 330 500 924 539 1.060 537 290 617 815 485 985 2.522
2025/202619.923 1.774 3.206 2.445 2.602 4.011 914 2.214 638 863 1.256 0 0
Totale 60.765